Personalised nutrition is emerging fast – as technologies like gene mapping and smartphones offer the potential for people to optimise nutrition, live healthier lives and reduce the burden of chronic disease like obesity and diabetes.
Omija fruit ethanol extract may be helpful to fight obesity and related metabolic disorders such as non-alcoholic fatty liver disease, dyslipidaemia, and insulin resistance, according to the results of a new study on mice fed a high-fat diet.
Ingredients giant BASF will collaborate with Irish start-up Nuritas on the discovery and commercialisation of novel functional peptides using DNA analysis and artificial intelligence (AI).
Belgian firm KitoZyme is planning a roll out of of medical device products that put restoring gut flora at centre stage, company told Nutraingredients after receiving two new certifications.
Wild banana (M. acuminata), which has long been used in traditional medicine in South East Asia, is worthy of further investigation to assess its functional food and nutraceutical development on a larger scale, a new academic review suggests.
The French food supplements trade group Synadiet has clarified that the Uvestérol D vitamin D product linked to an infant death before Christmas was a prescription-only medicine and not available as a food supplement to the public.
Indian-based but global-facing herbals player OmniActive Health Technologies has won a $35 million (€33m) investment from venture capitalist Everstone Group, as it pursues expansion and acquisition targets.
Only the seemingly foolish would have predicted 2016 would see the UK vote to leave the EU and Donald Trump win the US presidential election. But in the post-truth era, these are the facts.
A proprietary tomato extract – backed in EU health claim law to benefit blood circulation – has been shown to thin blood in healthy people – but less severely than aspirin and without typical side-effects.
The UK Advertising Standards Authority (ASA) has reversed its ruling against healthcare company Omega Pharma following previously omitted advice from the UK’s medicines regulator.
